Pralidoxime
پرالیدوکسیم
🧪 VariousCholinesterase reactivator (antidote)
Market / country: 🇺🇸 USA
Protopam (US)
🧮 Dose calculator
Organophosphate or muscarinic mushroom poisoning · Regimen source: FDA Protopam · Dosage and Administration — Adult intravenous dosing
- • After atropine (correct hypoxia first). In 100 mL saline over 15–30 min; max 200 mg/min. If weakness persists, second dose after about 1 h, then every 10–12 h. Little benefit beyond 36 h after exposure ends; observe 48–72 h. FDA Protopam · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⚠️ No absolute contraindications; relative: hypersensitivity to the drug. FDA Protopam · Contraindications
Important interactions
- • In organophosphate poisoning avoid morphine, theophylline, aminophylline, reserpine and phenothiazines; succinylcholine with caution. FDA Protopam · Dosage and Administration
Formulations
- 1 g vial (reconstitute; 10–20 mg/mL for IV infusion) — powder for injection 🇺🇸 USA FDA Protopam · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Protopam · Pregnancy
“Teratogenic Effects: Animal reproduction studies have not been conducted with pralidoxime chloride.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Protopam · Nursing Mothers
“Because many drugs are excreted in human milk, caution should be exercised when pralidoxime chloride is administered to a nursing woman.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Protopam · Pediatric Use
“There are no adequate and well-controlled clinical trials that establish the effectiveness of pralidoxime chloride in pediatric patients.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Protopam · Geriatric Use
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA014134
- DailyMed (FDA label)FDA Protopam
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDV03AB04
- Darooyab (Iran)Pralidoxime
🇮🇷 Registered in Iran Darooyab · G-1975/Pralidoxime
Dosage forms with Iranian generic codes, per Darooyab.
- 01643 · PRALIDOXIME 1000MG VIAL · ویال پرالیدوکسیم ۱۰۰۰ میلیگرم
- 06323 · PRALIDOXIME 200MG/10ML VIAL · ویال پرالیدوکسیم ۲۰۰ میلیگرم / ۱۰ میلیلیتر
- 21627 · PRALIDOXIME 500MG/10ML VIAL · ویال پرالیدوکسیم ۵۰۰ میلیگرم / ۱۰ میلیلیتر
- 22075 · PRALIDOXIME 500MG/20 ML AMP · آمپول پرالیدوکسیم ۵۰۰ میلیگرم / ۲۰ میلیلیتر
- 53051 · PRALIDOXIME IODIDE INJECTION, SOLUTION PARENTERAL 25 mg/1 mL 20 mL · محلول تزریقی پرالیدوکسیم یداید ۲۵ میلیگرم / ۱ میلیلیتر ۲۰ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Protopam · How SuppliedFDA Protopam · Dosage and Administration — Adult intravenous dosingFDA Protopam · Dosage and AdministrationFDA Protopam · Dosage and Administration — Pediatric intravenous dosingFDA Protopam · ContraindicationsFDA Protopam · PregnancyFDA Protopam · Nursing MothersFDA Protopam · Pediatric UseFDA Protopam · Geriatric UseFDA Protopam · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1975/Pralidoxime
- Clinical review⚠ Unverified